Urotensin II: A cardiovascular and renal update

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 2, 2008, Pages 199-204

  Carmine, Zoccali ^a,b   Mallamaci, Francesca ^a  

^a CNR Consiglio Nazionale delle Ricerche   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Chronic kidney disease; Coronary heart disease; End stage renal disease; Heart failure; Urotensin

Indexed keywords

UROTENSIN II;

BLOOD VESSEL TONE; CARDIOVASCULAR SYSTEM; CHRONIC KIDNEY FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART FAILURE; HEART FUNCTION; HEART PROTECTION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; VASOCONSTRICTION;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; KIDNEY; KIDNEY DISEASES; MICE; MICE, KNOCKOUT; RATS; UROTENSINS;

EID: 39149083023     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3282f49566     Document Type: Note

References (50)

1. Ashton N. Renal and vascular actions of urotensin II. Kidney Int 2006; 70:624-629.
2. McMaster D, Kobayashi Y, Rivier J, Lederis K. Characterization of the biologically and antigenically important regions of urotensin II. Proc West Pharmacol Soc 1986; 29:205-208.
3. Conlon JM, Arnold-Reed D, Balment RJ. Posttranslational processing of prepro-urotensin II. FEBS Lett 1990; 266:37-40.
4. Charles CJ, Rademaker MT, Richards AM, Yandle TG. Urotensin II: evidence for cardiac, hepatic and renal production. Peptides 2005; 26:2211-2214.
5. Sugo T, Murakami Y, Shimomura Y, et al. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem Biophys Res Commun 2003; 310:860-868.
6. Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999; 401:282-286.
7. Stirrat A, Gallagher M, Douglas SA, et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 2001; 280:H925-H928.
8. Tolle M, van der Giet M. Cardiorenovascular effects of urotensin II and the relevance of the UT receptor. Peptides 2007; 6 September [Epub ahead of print]. An extensive review of the cardiovascular and renal effects of urotensin II in health and disease.
9. Richards AM, Charles C. Urotensin II in the cardiovascular system. Peptides 2004; 25:1795-1802.
10. Wang YX, Ding YJ, Zhu YZ, et al. Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction. Am J Physiol Heart Circ Physiol 2007; 292:H348-H359.
11. Bolt GR, Itoh H, Lederis K, MacCannell KL. Differential antagonism of alpha-1 and alpha-2 adrenoceptor-mediated pressor responses by urotensin I, a selective mesenteric vasodilator peptide. J Pharmacol Exp Ther 1987; 242:284-291.
12. Lu Y, Zou CJ, Huang DW, Tang CS. Cardiovascular effects of urotensin II in different brain areas. Peptides 2002; 23:1631-1635.
13. Zou Y, Nagai R, Yamazaki T. Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett 2001; 508:57-60.
14. Maguire JJ, Davenport AP. Is urotensin-II the new endothelin? Br J Pharmacol 2002; 137:579-588.
15. Russell FD, Molenaar P, O'Brien DM. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 2001; 132:5-9.
16. Gong H, Wang YX, Zhu YZ, et al. Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat. J Appl Physiol 2004; 97:2228-2235.
17. Kompa AR, Thomas WG, See F, et al. Cardiovascular role of urotensin II: effect of chronic infusion in the rat. Peptides 2004; 25:1783-1788.
18. Zhu YZ, Wang ZJ, Zhu YC, et al. Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a 'vasoconstrictor' with a unique hemodynamic profile. Am J Physiol Heart Circ Physiol 2004; 286:H830-H836.
19. Tzanidis A, Hannan RD, Thomas WG, et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 2003; 93:246-253.
20. Douglas SA, Tayara L, Ohlstein EH, et al. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002; 359:1990-1997.
21. Ng LL, Loke I, O'Brien RJ, et al. Plasma urotensin in human systolic heart failure. Circulation 2002; 106:2877-2880.
22. Richards AM, Nicholls MG, Lainchbury JG, et al. Plasma urotensin II in heart failure. Lancet 2002; 360:545-546.
23. Heringlake M, Kox T, Uzun O, et al. The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul Pept 2004; 121:129-136.
24. Russell FD, Meyers D, Galbraith AJ, et al. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 2003; 285:H1576-H1581.
25. Harris GS, Lust RM, Katwa LC. Hemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval fistula. Peptides 2007; 28:1483-1489. An important study highlighting a protective effect of urotensin II in a chronic volume overload model.
26. Prosser HC, Forster ME, Richards AM, Pemberton CJ. Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury. Peptides 2007; 21 August [Epub ahead of print]. An intriguing experimental study in isolated perfused rat heart showing that urotensin II limits ischemia-reperfusion damage.
27. Shenouda A, Douglas SA, Ohlstein EH, Giaid A. Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma. J Histochem Cytochem 2002; 50:885-889.
28. Song W, Abdel-Razik AE, Lu W, et al. Urotensin II and renal function in the rat. Kidney Int 2006; 69:1360-1368.
29. Ovcharenko E, Abassi Z, Rubinstein I, et al. Renal effects of human urotensin-II in rats with experimental congestive heart failure. Nephrol Dial Transplant 2006; 21:1205-1211.
30. Zhang AY, Chen YF, Zhang DX, et al. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol 2003; 285:F792-F798.
31. Douglas SA, Dhanak D, Johns DG. From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 2004; 25:76-85.
32. Kemp W, Roberts S, Krum H. Increased circulating urotensin II in cirrhosis: Potential implications in liver disease. Peptides 2007; 6 September [Epub ahead of print].
33. Totsune K, Takahashi K, Arihara Z, et al. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 2004; 25:1809-1814.
34. Cheung BM, Leung R, Man YB, Wong LY. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 2004; 22:1341-1344.
35. Totsune K, Takahashi K, Arihara Z, et al. Role of urotensin II in patients on dialysis. Lancet 2001; 358:810-811.
36. Mallamaci F, Cutrupi S, Pizzini P, et al. Urotensin II in end-stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides. J Nephrol 2005; 18:727-732.
37. Langham RG, Kelly DJ, Gow RM, et al. Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am J Kidney Dis 2004; 44:826-831.
38. Balat A, Pakir IH, Gok F, et al. Urotensin-II levels in children with minimal change nephrotic syndrome. Pediatr Nephrol 2005; 20:42-45.
39. Aiyar N, Guida B, Ao Z, et al. Differential levels of 'urotensin-II-like' activity determined by radio-receptor and radioimmuno-assays. Peptides 2004; 25:1339-1347.
40. Lapp H, Boerrigter G, Costello-Boerrigter LC, et al. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol 2004; 94:93-97.
41. Gruson D, Rousseau MF, Ahn SA, et al. Circulatingurotensin II levels inmoderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers. Peptides 2006; 27:1527-1531.
42. Dschietzig T, Richter C, Bartsch C, et al. Flow-induced pressure differentially regulates endothelin-1, urotensin II, adrenomedullin, and relaxin in pulmonary vascular endothelium. Biochem Biophys Res Commun 2001; 289:245-251.
43. Joyal D, Huynh T, Aiyar N, et al. Urotensin-II levels in acute coronary syndromes. Int J Cardiol 2006; 108:31-35.
44. Zoccali C, Mallamaci F, Tripepi G, et al. Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease. Kidney Int 2006; 69:1253-1258.
45. Khan SQ, Bhandari SS, Quinn P, et al. Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. Int J Cardiol 2007; 117:323-328. The higher the urotensin II level, the lower the likelihood of adverse events post myocardial infarction.
46. Balat A, Karakok M, Yilmaz K, Kibar Y. Urotensin-II immunoreactivity in children with chronic glomerulonephritis. Ren Fail 2007; 29:573-578.
47. Mallamaci F, Cutrupi S, Pizzini P, et al. Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease. Am J Hypertens 2006; 19:505-510.
48. Ravani P, Tripepi G, Pecchini P, et al. Urotensin II is an inverse predictor of death and fatal cardiovascular events in chronic kidney disease. Kidney Int 2007; 17 October [Epub ahead of print]. This study extends to CKD the observation in ESRD that low plasma urotensin II predicts short survival and cardiovascular complications.
49. Zoccali C, Mallamaci F, Benedetto F, et al. Urotensin II and cardiomyopathy in end stage renal disease. Hypertension 2007. In press
50. Sidharta PN, Wagner FD, Bohnemeier H, et al. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther 2006; 80: 246-256.